The expression of CD38 (arbitrarily defined as a cut of ≥ 30% cells expressing CD38) has also been associated with resistance to standard therapy, shorter time to first treatment and shorter OS in patients with CLL (14). This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.